Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Lê LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP, Slapak C, Seymour L. Lê LH, et al. Among authors: de alwis dp. Cancer Chemother Pharmacol. 2005 Aug;56(2):154-60. doi: 10.1007/s00280-004-0942-7. Epub 2005 Apr 5. Cancer Chemother Pharmacol. 2005. PMID: 15809877 Clinical Trial.
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
Ryan CW, Matias C, Agulnik M, Lopez-Pousa A, Williams C, de Alwis DP, Kaiser C, Miller MA, Ermisch S, Ilaria R Jr, Keohan ML. Ryan CW, et al. Among authors: de alwis dp. Invest New Drugs. 2013 Feb;31(1):145-51. doi: 10.1007/s10637-012-9819-5. Epub 2012 Apr 27. Invest New Drugs. 2013. PMID: 22539091 Clinical Trial.
Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68-75].
Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Li M, Yamamoto N, Siu LL, Chartash E, Aboshady H, Jain L. Lala M, et al. Among authors: de alwis dp. Eur J Cancer. 2021 Feb;144:400. doi: 10.1016/j.ejca.2020.12.006. Epub 2021 Jan 4. Eur J Cancer. 2021. PMID: 33414065 No abstract available.
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
Gordon MS, Ilaria R Jr, de Alwis DP, Mendelson DS, McKane S, Wagner MM, Look KY, LoRusso PM. Gordon MS, et al. Among authors: de alwis dp. Cancer Chemother Pharmacol. 2013 Jan;71(1):21-7. doi: 10.1007/s00280-012-1917-8. Epub 2012 Dec 11. Cancer Chemother Pharmacol. 2013. PMID: 23228983 Clinical Trial.
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.
Simon GR, Ilaria RL Jr, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR. Simon GR, et al. Among authors: de alwis dp. Cancer Chemother Pharmacol. 2011 Nov;68(5):1233-41. doi: 10.1007/s00280-011-1593-0. Epub 2011 Mar 23. Cancer Chemother Pharmacol. 2011. PMID: 21431416 Free PMC article. Clinical Trial.
59 results